NEUROTECH INTERNATIONAL LIMITED Neurotech International Limited Share Price
Equities
NTI
AU000000NTI9
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.091 AUD | +1.11% |
|
-1.09% | +31.88% |
| 04-17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
| 04-17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
| Sales 2022 | 608K 395K 31.6M | Sales 2023 | 1.19M 776K 62.12M | Capitalization | 34.96M 22.7M 1.82B |
|---|---|---|---|---|---|
| Net income 2022 | -3M -1.95M -156M | Net income 2023 | -7M -4.55M -364M | EV / Sales 2022 | 77.3 x |
| Net cash position 2022 | 1.9M 1.23M 98.58M | Net cash position 2023 | 5.03M 3.26M 261M | EV / Sales 2023 | 25.1 x |
| P/E ratio 2022 |
-14.5
x | P/E ratio 2023 |
-4.1
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.08% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.11% | ||
| 1 week | -1.09% | ||
| Current month | -17.27% | ||
| 1 month | -13.33% | ||
| 3 months | +1.11% | ||
| 6 months | +56.90% | ||
| Current year | +31.88% |
1 week
0.09
0.10
1 month
0.090.12
Current year
0.070.13
1 year
0.030.13
3 years
0.030.13
5 years
0.000.13
10 years
0.000.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Operating Officer | - | 07/03/22 | |
Erlyn Dawson
SEC | Corporate Secretary | - | 15/04/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Davies
CHM | Chairman | - | 15/04/19 |
Thomas Duthy
BRD | Director/Board Member | - | 31/08/22 |
Gerald Quigley
BRD | Director/Board Member | - | 06/07/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 0.091 | +1.11% | 1 018 382 |
| 30/04/24 | 0.09 | 0.00% | 953,583 |
| 29/04/24 | 0.09 | 0.00% | 2,534,868 |
| 26/04/24 | 0.09 | 0.00% | 1,439,697 |
| 24/04/24 | 0.09 | -2.17% | 6,485,682 |
Delayed Quote Australian S.E., May 01, 2024 at 06:51 am
More quotes
Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused on the development and commercialization of neurological solutions focused predominately on pediatric neurological disorders. The Company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its NTI/Dolce cannabis strains. It is also commercializing Mente, a home therapy to increase engagement and improve relaxation in autistic children with elevated delta-band brain activity. Its product, Mente Autism, assists with the management of children with autism spectrum disorder (ASD). Its development program NTI164 completed a Phase I/II clinical trial to treat patients with autism spectrum disorder (ASD). Mente Autism is a portable, electroencephalographic (EEG) medical device for home use in the form of a headband that uses closed-loop neurofeedback to helo-relax the minds of children with ASD.
Calendar
27/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +31.88% | 59.46M | |
| +2.21% | 3.41B | |
| -3.00% | 164M | |
| -14.17% | 82.88M |
- Stock Market
- Equities
- NTI Stock
